Company intelligence / Profile preview

Cavos Biotech

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Cavos Biotech has developed a proprietary computational platform that analyzes hundreds of animal genomes to uncover genetic bases for extraordinary cancer resistance and longevity. The company aims to translate these findings into precision therapeutics that mimic naturally occurring anti-cancer mechanisms. No clinical results have been reported yet; the company appears preclinical.

Therapeutic areas: OncologyImmunology
Modalities: Genomic algorithms for target discoverylikely small molecules or biologics as therapeutics (inferred from drug development focus)
Industry: Biotech

Beyond the preview

Go deeper on Cavos Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cavos Biotech.

Explore the full profile